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Abstract
Background: Cancer survivorship has emerged as an important aspect of oncology due to the possibility of
physical and psychosocial complications. The purpose of this study was to assess the feasibility of the Ambulatory
Medical Assistance for After Cancer (AMA-AC) procedure for monitoring lymphoma survivorship during the first year
after chemotherapy.
Methods: AMA-AC is based on systematic general practitioner (GP) consultations and telephone interventions
conducted by a nurse coordinator (NC) affiliated to the oncology unit, while an oncologist acts only on demand.
Patients are regularly monitored for physical, psychological and social events, as well as their health-related quality
of life (HRQoL). Inclusion criteria were patients newly diagnosed with non-Hodgkin or Hodgkin lymphomas, who
had been treated with anthracycline-based chemotherapy and were in complete remission after treatment.
Results: All 115 patients and 113 collaborating GPs agreed to participate in the study. For patients who achieved
one year of disease-free survival (n = 104) their assessments (438 in total) were fully completed. Eleven were
excluded from analysis (9 relapses and 2 deaths). The most frequent complications when taking into account all
grades were arthralgia (64.3 %) and infections (41.7 %). About one third of patients developed new diseases with
cardiovascular complications as the most common. Psychological disorders such as anxiety, depression and
post-traumatic stress disorder were diagnosed in 42.6 % of patients. The data collected showed that Hodgkin
lymphoma patients, females, and patients with lower HRQoL (mental component) at study entry were at greater
risk for developing at least one psychological disorder.
Conclusion: This study showed that AMA-AC is a feasible and efficient procedure for monitoring lymphoma
survivorship in terms of GP and patient participation rates and adherence, and provides a high quality of operable
data. Hence, the AMA-AC procedure may be transferable into clinical daily practice as an alternative to standard
oncologist-based follow-up.
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Background
Cancer survivorship has recently emerged as an import-
ant aspect of cancer patient trajectory. Cross-sectional
studies and registry-based data analyses have docu-
mented that cancer survivors present with a variety of
troubles that can lead to a decrease in their health-
related quality of life (HRQoL). Compared to that of
solid tumors (notably breast cancers), lymphoma survivor-
ship has received little attention, but studies examining
the course of morbidity in Non-Hodgkin lymphoma
(NHL) and Hodgkin lymphoma (HL) survivorship have
revealed that these patients experience psychological
disorders (e.g., anxiety, depression, post-traumatic stress
disorder [PTSD]) [1–3], delayed return to work [4], and a
subsequent decrease in their HRQoL [3, 5]. Beside these
complications, other severe concerns include the develop-
ment of cardiovascular diseases and second malignancies,
while relapse also remains possible, especially during the
first 24-months post-therapy [6].
Since the development of therapies to treat NHL and
HL patients, the number of survivors has increased and
is now estimated at 170,000 cases in the USA [1], 38,000
in Germany [7] and 35,000 in France [8]. However, one
of the main difficulties in managing cancer survivorship
is how to detect complications such as those listed
above. Addressing this requires a consideration of the
role of each care provider who is in contact with cancer
survivorship patients. In theory, cancer patient survivor-
ship surveillance involves a fair and effective collaboration
between oncologists, general practitioners (GPs) and po-
tentially other specialists depending on the nature of any
complications. Oncologist contact is mainly through
scheduled regular visits whereas GPs mainly operate as
the first point of contact for patients experiencing symp-
toms related or not to cancer or treatment. This so-called
“shared care” model has been supported by public health
decision-makers and is largely favored by GPs. However,
this model has been seriously questioned on the basis of
several considerations related to both GPs and hospital in-
sufficiencies. When surveyed, GPs reported not feeling
comfortable with cancer survivorship management [9]. In
general, GPs are thought to be poorly informed about the
nature and risk of late complications, especially delayed
adverse effects of therapies [10, 11], and they are not fa-
miliar with the psychological and social aspects of cancer
patients [9]. Thus, it is not surprising that the majority of
patients prefer to be followed-up by their oncologist ra-
ther than their GP, as has been reported for breast cancer
survivors [12]. These considerations may also explain why
the shared care model is less popular in the oncologist
community [13]. However, it has become more and more
evident that oncologist-based survivorship follow-up also
suffers from a number of flaws since, despite being
the most common model used, it appears that hospital
follow-up is cursory and poorly adapted to the detection
and graduation of psychological disorders, professional
difficulties and HRQoL degradation [14]. Moreover, re-
lapse or associated diseases, if they occur, are often diag-
nosed outside of a review visit [15]. Thus, the standard
hospital-based protocol of appointments is possibly not
the most productive and effective health care model for
cancer survivorship. In a large recent survey dealing with
gynecological cancer follow-up in the United Kingdom,
Leeson et al. described a switching of practices, with trad-
itional follow-up being replaced by telephone follow-up in
25 % of cases [16].
Telephone intervention, generally performed by spe-
cialized nurses (nurse coordinators [NC]), has been used
at different stages in the cancer patient trajectory, in-
cluding the early steps of diagnosis (the concept of a
“Patient Navigator”) [17], during the management of ad-
vanced cancers [18], and whilst undergoing psychother-
apy treatment for PTSD [19]. Most of these studies have
shown clinical benefits. In a previous report, we de-
scribed the Ambulatory Medical Assistance (AMA) pro-
ject, a new modality of patient management for diffuse
large B-cell lymphoma (DLBCL) patients undergoing
therapy with R-CHOP or R-CHOP-derived protocols.
AMA is based on scheduled appointments for patient
phone calls from home with a NC during their active
treatment phase. AMA has been found to be feasible
and very effective in both its triage function and in
saving medical time [20]. Moreover, it appears that
AMA not only generates great satisfaction among pa-
tients and caregivers but has also improved chemother-
apy observance, reduced secondary hospitalization and,
perhaps, decreased the toxic death rate [20].
Based on the success of AMA, we designed the
AMA-AC (Ambulatory Medical Assistance - After
Cancer) model, a variant of the shared care model
which is based on close collaborations between a NC
and the patient’s GP for the surveillance of lymphoma
survivors. The present study is based on an ongoing
prospective cohort of 115 lymphoma patients treated
with anthracycline-containing regimens. This study
was aimed at investigating whether AMA-AC is a
feasible procedure for monitoring a patient’s physical,




To be selected for the AMA-AC program, volunteers
must have received treatment for B- or T-cell derived
NHL or advanced HL, with their first-line of treatment
consisting of an anthracycline-based therapy (i.e., CHOP21,
R-CHOP21, R-CHOP-derived, ABVD or BEACOPP)
at the Toulouse University Hospital. They also must
Compaci et al. BMC Cancer  (2015) 15:781 Page 2 of 13
have achieved a complete response according to the
Cheson’s criteria [21], and been followed-up by a GP
who had agreed to participate in the program. Patients
under 18 years of age at diagnosis, or who were physically
and/or mentally unable to participate in the program were
not included. The study has been approved by the ethical
committee of the Toulouse University Hospital and all
participants gave their written informed consent. Between
1st November 2011 and 1st November 2013, 115 patients
joined the AMA-AC program.
AMA-AC program design
The program is presented in detail in Fig. 1. Briefly, the
AMA-AC program consisted of one initial visit to an on-
cologist in the presence of a NC. The patient received a
handbook which contained all information related to the
AMA-AC procedure and a calendar for the scheduled
regular appointments with their GP (physical visit)
and with the NC (phone call at patient’s home). This
handbook was also forwarded by e-mail to the pa-
tient’s GP who in addition received a clinical report
form (CRF) specially prepared to help detect any
physical events. The AMA-AC program consisted of
quarterly follow-up assessments for monitoring any
medical, psychological and social events. It encom-
passed GP appointments, self-perceived evaluation of
HRQoL and mental health, and phone calls conducted by
the NC. The CRF contained 41 items related to three
groups of symptoms: symptoms compatible with a relapse,
symptoms suggesting previously undocumented comor-
bidities (e.g., cardiovascular complications), and symptoms
classified as adverse drug effects (e.g., neuropathy). Im-
portantly, the informed consent form clearly stated that
the program did not include any systematic appointments
with an oncologist; however the patients were able to
consult their oncologist on demand at any time at the
hospital. Throughout the program the CRF was completed
by the GP during each GP consultation and forwarded by
Fig. 1 Scheme of the AMA-AC procedure
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e-mail to the NC. Regular biological analyses (i.e., blood
cell count, liver and kidney function, C-reactive protein,
lactate dehydrogenase, protein electrophoresis) were also
performed at a location near to the patient’s home and
forwarded to the NC. Information about psychological
events was gathered through patient self-evaluation of
health outcome and through NC phone calls. In addition,
during the telephone interview the NC questioned pa-
tients regarding their social and professional status or any
other changes (e.g., return to work, disability pensioning,
personal resources). The resulting file, compiled by the
NC, included physical, psychological, social and pro-
fessional sections. The NC was in charge of forward-
ing this data to the oncologist, who summarized all
the information and if necessary would call the pa-
tient or their GP for clarification, or as a last degree
would call the patient in for a visit at the hospital. In
each case, the oncologist then forwarded his conclu-
sion to the GP by post. In some cases, symptom de-
tection required referrals to additional clinical and
psychosocial providers. For the most part these spe-
cialists were designated by the GP and worked in pri-
vate practice. The NC (or oncologist) was responsible
for making contact with these specialists, planning
appointments, and addressing all relevant information.
Data collected by the AMA-AC program
Initial patient characteristics
Individual, disease-related and treatment-related initial
characteristics were collected. Individual characteristics
included gender, age at inclusion into the AMA-AC pro-
gram (M0 =Month 0), health insurance coverage, famil-
ial status (i.e., whether patients lived alone or not), level
of education, occupational status, and salary per month.
Disease-related characteristics included histology type,
Ann Arbor stage, Eastern Cooperative Oncology Group
(ECOG) performance status, Charlson comorbidity index
(CCI) [22, 23], prognostic index with regard to histological
type: the revised international prognostic index (IPI) for
DLBCL [24], the follicular lymphoma prognostic index
(FLIPI) for follicular lymphoma [25], and the Hasenclever
international prognostic index for advanced HL [26].
Treatment characteristics corresponded to the first-
line chemotherapy regimens dichotomized as “conven-
tional” for CHOP21, R-CHOP21, ABVD, and R-mini
CHVP and “intensified” for R-ACVBP, irrespective of
whether this was followed or not by autologous
hematopoietic stem cell transplantation (ASCT), R-
COPADM and BEACOPP.
Medical events
Physical events were assessed in the 41-item CRF
completed during GP appointments and included
symptoms potentially related to relapse, newly
diagnosed comorbidities, and adverse drug effects
(see Additional file 1 for the complete CRF).
Psychological disorders included anxiety, depression
and post-traumatic stress disorder (PTSD). Anxiety and
depression were assessed by quarterly phone calls (M3,
M6, M9 and M12) according to the French version of
the 14-item Hospital Anxiety and Depression Scale
(HADS) [27, 28], which is divided into two subscales:
anxiety (HAD-A) and depression (HAD-D). A score be-
tween 0 and 21 was calculated for each subscale with a
higher score indicating a higher level of anxiety or de-
pression. For each quarter, the overall incidence of anx-
iety and depression was calculated as the ratio of new
cases (defined by a HAD-D or HAD-A score above 8)
over the number of patients at risk at the beginning of
the study period (i.e., those free of anxiety or depres-
sion). The prevalence of anxiety and depression at each
quarter was also computed as the ratio of total number
of cases (defined by a HAD-D or HAD-A score above 8)
over the total number of patients followed in the period.
However, although the self-perceived questionnaire mea-
sured the extent of anxiety or depressive symptoms ex-
perienced, this could not replace clinical diagnosis,
therefore GPs were contacted in cases of noticeable
values and, if needed, patients were referred to special-
ists. PTSD was measured using the French version of
the PTSD checklist (PCL) [29–31], mailed to the patients’
homes for assessment at M6 and M12. The PCL assessed
the presence of PTSD symptoms by scoring responses
related to three symptom groups: re-experiencing,
avoidance and hyper-arousal. The PCL is a 17-item
self-reporting checklist measuring PTSD. It is delin-
eated in the fourth edition of the Diagnostic and Stat-
istical Manual of Mental Disorders (DSM-IV) [32],
and was adapted for the diagnosis and treatment of
cancer. Patients were asked to rate their experience of
each of the 17 symptoms on a five point scale, from
1 (not at all) to 5 (extremely) during the previous
month. The PCL total scores ranged from 17 to 85.
Patients with a total score ≥44 were considered to
have PTSD. In addition, a computer tomography (CT)
scan was performed on all patients at M6.
Complementary information
Professional and social parameters were also gathered
during the quarterly phone interviews, including any re-
turn to work, changes in home address and changes in
cohabiting status.
HRQoL was assessed using the self-reported French
version of the SF-36 [33–36], mailed to the patients’
homes, at M0 and M12. The 36 items on this list were
distributed into two subscales: the Physical Component
Score (PCS) and the Mental Component Score (MCS),
scored from 0 (poor) to 100 (excellent).
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Data collection and analysis
An anonymized database was used to collect all informa-
tion related to the AMA-AC program. This database
was secured and managed by an external service device
in accordance with ad hoc regulatory committees. In
order to determine the strength of the relationship be-
tween each of the variables (PTSD, HAD-Depression,
HAD-Anxiety, SF36-MCS, and SF36-PCS scores) mea-
sured at M0, M3, M6, M9 and M12, we generated a
Pearson correlation matrix. A correlation coefficient of
1.0 indicated a positive correlation and a value of −1.0
indicated a negative correlation. According to the guide-
lines by Cohen et al. [37], a correlation coefficient be-
tween 0.10 and 0.29 corresponds to a small strength of
correlation, 0.30 to 0.40 denotes a medium correlation
and 0.50 to 1.0 signifies a high correlation between the
variables. We implemented a multivariate logistic regres-
sion model adjusted for variables statistically associated
with the outcome in bivariate analyses with a risk alpha
of 20 %, except for the first-line chemotherapy regimen
which was forced in the model. Interactions between the
covariates were verified for each model. Assumptions
and model fit were measured using the Hosmer and
Lemshow test. A two-sided p-value <0.05 was consid-
ered as statistically significant for the multivariate model.
Statistical analyses were performed using SAS®software
version 9.4 (SAS institute, Cary, NC).
Results
Implementation of AMA-AC
A total sample of 115 patients, followed by 113 GPs (2
of whom each monitored 2 patients), entered into the
AMA-AC program. Patient characteristics are listed in
Table 1, data were exhaustive for the characteristics
assessed, with the exceptions of salary (77 % complete),
Ann Arbor stage and prognosis index (97 % complete
for both). Histology subtypes were as follows: diffuse
large B-cell lymphoma (DLBCL): 64 patients (55.7 %),
follicular lymphoma (FL): 27 patients (23.4 %), Hodgkin
lymphoma: 18 patients (15.7 %), and other non-Hodgkin
lymphoma (NHL): 6 patients (5.2 %). All GPs agreed to
participate in the program but 11 patients were excluded
due to relapse (n = 9) and death (n = 2) related to causes
other than the primary cancer. Thus, a total of 104
patients were followed-up for at least one year. The
AMA-AC procedure consisted of 438 patient assess-
ments: 115 at M3, 113 at M6, 106 at M9, and 104 at
M12. The auto-questionnaires (SF-36, PCL) were com-
pleted at home and sent to the NC in all cases. The GPs
returned each CRF (100 % validity), and reported that
these required about 15 min to complete. The median
time for the nurse-led phone calls was 30 min. The on-
cologists spent a median time of 10 min for the synthesis
and summary letter (via voice recognition dictation).
Altogether, the procedure represented 55 min per quar-
ter (i.e., 220 min per patient per year of follow-up). A
significant gain of time was obtained through auto-
evaluation of the PCL and SF-36 by the patient. Accord-
ing to the AMA-AC procedure, patients were able to
visit an oncologist on demand. Among the 104 patients
free of relapse and alive at M12, only 6 patients (6.5 %)
returned to the hospital during the first 12 months of
follow-up for the following reasons: fear of relapse
based on imaging or subjective symptoms (which
were not confirmed; n = 4) and delayed neutropenia
(post-rituximab neutropenia) requiring bone marrow
analysis (n = 2).
Physical events during follow-up
Treatment-related complications
The prevalence of physical disorders at each quarterly
assessment are depicted in Table 2. For the entire one-
year follow-up, the most frequent complications when
taking into account all grades were: arthralgias (64.3 %)
and infections (41.7 %), the latter being most often asso-
ciated with mild hypogammaglobulinemia. Indeed, al-
though 47.0 % of patients displayed immunoglobulin
levels lower than 8 g/L, severe hypogammaglobulinemia
(<3 g/L) was rare (2.6 %). A third of infections were
pneumonia or sinusitis. Herpes zoster was infrequent
(n = 3). Neuropathies due to vincristine or vinblastine
were identified in 24.3 % patients, with all grades in-
cluded in this, however these resolved over time
(16.3 % at M12). As an unexpected finding, gastric
symptoms were frequent (17.4 % of patients). Among
the patients with gastric symptoms, endoscopy was
performed in about one third. Libido changes (most
often in males) were observed in 14.8 % of patients.
Among men, erectile dysfunction was observed in 20/64
patients (31.3 % of patients. Forty percent of male patients
with erectile dysfunction were treated with tadalafil. The
occurrence of symptomatic osteoporosis during the first
12 months of survivorship was also common (13.3 % of
patients; exclusively females). We found no influence of
histology subtype (DLBCL, FL or HL), on the distribution
of treatment-related complications, with the exception of
hypogammaglobulinemia which was more frequently ob-
served for DLBCL.
Relapse
Within the first year of survivorship nine patients re-
lapsed: (n = 3 before M6, n = 6 between M6 and M12).
In all cases the relapse was suspected by the patients
themselves and was confirmed by clinical symptoms and
examination by GPs. Consequently, patients were re-
examined by an oncologist on demand to confirm
the relapse by biopsy and histological analysis at the
hospital. The CT scans performed at M6 (n = 108
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examinations) played no part in detecting relapses
(data not shown).
Newly-diagnosed comorbidities
About one third of patients developed new diseases dur-
ing the early stages of survivorship (Table 2). The most
frequent complications were cardiovascular diseases
(n = 16) with sometimes more than one per patient:
thromboembolic diseases (n = 5), arrhythmias (n = 9),
atherosclerotic heart disease resulting in myocardial
infarction (n = 1), severe pericarditis (n = 1) and arter-
ial hypertension (n = 1). The thyroid was also affected
in 6.1 % of patients: thyroid insufficiency (n = 3, detected
by biological testing) and thyroid nodules (n = 4) among
which one cancer was discovered. Prostatic adenomas or
prostatitis were less common (4.7 % of patients). One pa-
tient who presented as a relapse in fact had a secondary
lymphoma (marginal zone lymphoma complicating a
follicular lymphoma). The CT scan performed at M6,
although ineffective at detecting relapses, raised major
concerns in 4 out of 111 patient examinations (3.6 %), and
led to the diagnosis of one pancreatic cancer, one intra-
ductal papillary mucinous neoplasm of the pancreas
(preneoplasic lesions), one pulmonary embolism, and
one asymptomatic choledocallithiasis. Overall, among
106 patients not showing a relapse, 11 of them (10.4 %)
developed serious non-haematological diseases within the
first year of follow-up, among which there were 3
adenocarcinomas.
Non-physical events during follow-up
Psychological disorders (PTSD, anxiety or depression)
During the first phone call (M3) the prevalence of
anxiety was as high as 20.0 % but decreased over time
(14.8 % at M12). The prevalence of depression was less
frequent (9.6 % at M3 and 6.5 % at M12). The preva-
lence of PTSD ranged between 14.8 % of 115 patients at
M0 and 17.6 % of 104 patients at M12 (Fig. 2). Over the
first 12 months, 42.6 % of patients presented with at
least one of the three psychological disorders (anxiety,
depression or PTSD): 20.8 % patients (n = 24/115) had
Table 1 Characteristics of the 115 patients included in the
AMA-AC program
Patient characteristics at diagnosis/entry to AMA-AC (n = 115)
Gender Men (n;%) 64 (55.7 %)
Age (years)




General health system 104 (90.4 %)
Others (Agriculture, freelancers) 11 (9.6 %)
Cohabiting status (n;%)
Living together (married, living in partnership) 87 (75.6 %)
Living alone (single, divorced, widowed) 28 (24.4 %)
Level of education (n;%)
Lower educational status (≤high school degree) 64 (55.7 %)
Higher educational status (>high school degree) 51 (44.4 %)
Occupational status (n;%)
In activity (employed) 61 (53.0 %)
Without activity (without employment, retired,
unemployed)
54 (47.0 %)
Salary net/month (n;%) (n = 86)
No salary 3 (3.5 %)
<380€ - 1070€ 20 (23.3 %)
>1070€ - 1830€ 24 (27.9 %)
>1830€ - 2290€ 12 (14.0 %)
>2290€ - 4570€ 27 (31.4 %)
Disease-related characteristics
Histology (n;%)
Diffuse large B-cell lymphoma (DLBCL) 64 (55.7 %)
Other NHL 33 (28.6 %)
Hodgkin lymphoma 18 (15.7 %)
Ann Arbor stage (n;%) (n = 112)
I/ II 25 (22.3 %)
III/ IV 87 (77.7 %)
Performance status (n;%)
≤ 1 96 (83.5 %)
≥ 2 19 (16.5 %)
Charlson comorbidity index (n;%)
0 88 (76.5 %)
1 9 (7.8 %)
≥ 2 18 (15.7 %)
Prognosis (according to IPI, FLIPI, IPS) (n = 112)
Good 19 (16.52 %)
Medium 59 (51.30 %)
Bad 24 (20.87 %)
Table 1 Characteristics of the 115 patients included in the
AMA-AC program (Continued)
Treatment-related characteristics
Type of treatment line (n;%)a
Conventional 84 (73.0 %)
Intensified 31 (27.0 %)
Abbreviations: IPI International Prognostic Index; FLIPI Follicular Lymphoma
International Prognostic Index; IPS International Prognostic Score
(Hasenclever Index)
aType of treatment line: Conventional: CHOP21: 4 (3.5 %), R-CHOP21: 65
(56.5 %), R-mini-CHOP: 3 (2.6 %), ABVD: 12 (10.4 %); Intensified: R-ACVBP: 24
(20.9 %),
R-COPADM: 1 (0.9 %), BEACOPP: 6 (5.2 %)
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one disorder, 12.2 % (n = 14/115) had two and 9.6 %
(n = 11/115) had all three.
Health-related Quality of Life (HRQoL)
HRQoL was measured at M0 and M12 for patients
who had achieved a complete one-year free of
lymphoma (n = 104 patients). As depicted in Fig. 3,
the physical and mental aspects of HRQoL improved
during this period. All components were significantly
improved between M0 and M12 excepted for general
and mental health. Although the HRQoL improved
in general during the one year follow-up, some
patients remained in a poor condition with 20 % of
patients still displaying an MCS or PCS ≤ 50 at M12
(Fig. 3).
Professional and social changes
The majority of patients were in employment before
treatment (61/115). However, 57 (93 %) went on sick
leave during the active treatment phase and 45 of these
returned to work (78.9 %) either in a full time (n = 32)
or part-time capacity (n = 13). Among the total sample
almost 10 % showed a reduction in financial resources
and 4.3 % changed their home address. A change in
marital status was infrequent over this period (1.7 %).
Impact of psychological disorders on HRQoL and risk
factors
A Pearson correlation matrix was constructed for each
variable (PTSD, HAD-Depression, HAD-Anxiety, SF36-
MCS, and SF36-PCS scores), measured at M0, M3, M6,
M9 and M12 (Table 3). This matrix shows a constant
connection between all of these variables. Bivariate ana-
lysis revealed that several factors were associated with
the probability of developing at least one psychological
disorder during one year of follow-up. These included
gender (female), age (<60 years), histology (HL) and,
more importantly, lower mental and physical HRQoL at
M0. Thus, multivariate analysis showed that patients po-
tentially at risk for developing at least one psychological
disorder are females, patients diagnosed with HL, and
patients with lower self-perceived mental HRQoL at M0
(Table 4).
Discussion
The aim of this prospective cohort study was to investi-
gate the feasibility of using the AMA-AC procedure to
monitor lymphoma survivors for any physical, psycho-
logical and social events that occurred during their first
year after therapy. The implementation of the AMA-AC
procedure showed not only that it could be feasibly used
Table 2 Monitored treatment-related complications and comorbidities during one year of follow-up
Phone call 1 Phone call 2 Phone call 3 Phone call 4
Prevalence of complications Month 3 (n = 115) Month 6 (n = 113) Month 9 (n = 106) Month 12 (n = 104) Total (n = 115)
n % n % n % n % n %
Treatment-related complications
Neuropathy
Peripheral 26 22.6 % 24 21.2 % 22 20.7 % 17 16.3 % 28 24.3 %
Central 1 0.9 % 2 1.8 % 0 0.0 % 2 1.9 % 2 1.7 %
Infections
Pulmonary 14 12.2 % 8 7.1 % 8 7.5 % 8 7.7 % 38 33.0 %
Ear, nose and throat 5 4.4 % 5 4.4 % 8 7.5 % 5 4.8 % 23 20.0 %
Urinary 4 3.5 % 4 3.5 % 3 2.8 % 2 1.9 % 13 11.3 %
Hypogammaglobulinaemia 15 13.0 % 36 31.9 % 43 40.6 % 31 29.8 % 54 47.0 %
Gastritis/ulcer 14 12.2 % 17 15.0 % 18 17.0 % 11 10.6 % 20 17.4 %
Arthralgia 52 45.2 % 57 50.4 % 47 44.3 % 44 42.3 % 74 64.3 %
Libido decrease 16 13.9 % 7 6.2 % 10 9.4 % 10 9.6 % 17 14.8 %
Erectile dysfunction (n = 64) 11 17.2 % 6 9.5 % 7 10.9 % 6 10.2 % 20 31.3 %
Osteoporosis 9 7.8 % 10 8.9 % 9 8.5 % 12 11.5 % 15 13.3 %
Comorbidities
Cardiovascular complications (≥1/phone call) 6 5.2 % 4 3.5 % 6 5.7 % 10 9.6 % 16 13.9 %
Disorders of thyroid gland 5 4.4 % 5 4.4 % 4 3.8 % 7 6.7 % 7 6.1 %
Disorders of prostate (n = 64) 3 4.7 % 2 3.2 % 2 3.1 % 2 3.1 % 3 4.7 %
Second cancer 1 0.9 % 1 0.9 % 1 0.9 % 2 1.9 % 4 3.5 %
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for this purpose but also that it is transferable into clin-
ical daily practice.
All patients voluntarily entered into the study and ac-
cepted the conditions of the program, that they would
be mainly monitored by their GP and the NC, with the
oncologist being available only upon request. This unre-
stricted approval could be due to the climate of confi-
dence established between the patient and the NC
during the active phase of treatment as part of the AMA
process [20]. Indeed, we believe that AMA during the
active phase (now designated as AMA1 in our institu-
tion) played an important role in the success of this
AMA-AC program, and that AMA1 and AMA-AC are
highly complementary (all patients enrolled in AMA-AC
were initially enrolled in AMA1). The fact that the
majority of our patients were well-educated and young
(a median age of 55 years) may have also facilitated not
only acceptance but also adherence. This selection bias
could raise some concerns with respect to the
generalizability of our findings. Thus, it remains possible
that in a wider population a loss of adherence could
occur concerning one or several components of the pro-
cedure such as attending GP appointments, taking NC
calls or returning self-reported questionnaires. It is also
important to note that all GPs participated in the AMA-
AC, a total of 113 GPs (2 of whom each monitored 2 pa-
tients). This high rate of GP acceptance (113/113) prob-
ably reflects the motivation of GPs to contribute to
survivorship management in association with the oncol-
ogy hospital unit according to the “shared care” model.
AMA-AC is a time-consuming procedure, requiring a
mean of 55 min per quarter per patient, without taking
into account the time spent by the patient in completing
the auto-questionnaires (PCL and SF-36). Of these
55 min, the largest time contribution was from the NC
(30 min) followed by the GP (15 min) and finally the on-
cologist (10 min). Compared to the standard surveillance
performed in our department (a 30 min visit every
3 months for the first year, then every 6 months for
5 years), there was a significant reduction in medical
time with the oncologist (30 % reduction). The fact that
Fig. 2 Prevalence and incidence of PTSD (top), measured every
6 months, and anxiety (middle) and depression (bottom) evaluated
every 3 months
Fig. 3 Health-Related quality of life (SF-36) evaluation with the SF-36 at the entry of AMA-AC (n = 114 patients) and after 12 months (n = 104 patients)
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Table 3 Pearson correlation coefficients for the scores of the PTSD checklist (at months 1, 6 and, 12), the hospital anxiety and depression scale (Months 3, 6, 9 and 12), and the































1 0.79649 0.73146 0.56455 0.55338 0.53787 0.59773 0.44034 0.39448 0.38274 0.47341 −0.51828 −0.41293 −0.59287 −0.54638 PTSD
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 (M0)
1 0.79187 0.58923 0.6597 0.65753 0.7029 0.41921 0.47819 0.48008 0.49995 −0.5599 −0.4472 −0.64859 −0.56404 PTSD
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.00016 <.0001 <.0001 (M6)
1 0.45231 0.52977 0.59971 0.64537 0.33995 0.39253 0.46842 0.54995 −0.38771 −0.30926 −0.69486 −0.54733 PTSD
<.0001 <.0001 <.0001 <.0001 0.0004 <.0001 <.0001 <.0001 <.0001 0.0013 <.0001 <.0001 (M12)
1 0.65131 0.70539 0.62431 0.42708 0.30713 0.29832 0.34666 −0.3969 −0.36314 −0.45017 −0.37952 HADA
<.0001 <.0001 <.0001 <.0001 0.0009 0.0015 0.0002 <.0001 <.0001 <.0001 <.0001 (M3)
1 0.74176 0.71154 0.40855 0.48015 0.47148 0.43145 −0.38351 −0.4053 −0.43999 −0.40748 HADA
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 (M6)
1 0.77938 0.47043 0.44302 0.55754 0.49862 −0.37517 −0.36301 −0.49752 −0.43972 HADA
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 (M9)
1 0.38733 0.49511 0.51986 0.55888 −0.48623 −0.43266 −0.51551 −0.46204 HADA
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 (M12)
1 0.64098 0.58671 0.56799 −0.48358 −0.39613 −0.42135 −0.39067 HADD
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 (M3)
1 0.57086 0.58342 −0.40282 −0.36483 −0.41359 −0.39385 HADD
<.0001 <.0001 <.0001 <.0001 <.0001 <.0001 (M6)
1 0.73002 −0.31758 −0.31682 −0.5145 −0.45989 HADD
<.0001 0.0007 0.0007 <.0001 <.0001 (M9)
1 −0.39559 −0.37602 −0.6048 −0.49074 HADD
<.0001 <.0001 <.0001 <.0001 (M12)
1 0.78154 0.49547 0.47986 SF36 MCS
<.0001 <.0001 <.0001 (M0)
















the total time spent for patient management in AMA-
AC was higher that than of our standard surveillance
procedure would be expected to correlate with the su-
periority of AMA-AC in gathering information of differ-
ent types and from different sources. Medico-economic
evaluation of AMA-AC is beyond the scope of our
study. However, one can speculate that the increased
total time spent for patient management might be
largely counterbalanced by the decrease in transporta-
tion costs. It is also possible that the limitation of visits
would result in decreased absenteeism and subsequently
an improved productivity for young and professionally
active patients. These questions deserve more specific
investigation.
This study has shown that AMA-AC could be an ef-
fective procedure for detecting physical events during
the early trajectory of lymphoma survivorship. Until
now, the occurrence or persistence of morbid mani-
festation had not been thoroughly examined during
this period by prospective studies. Our prospective
study shows a high occurrence of disabling symptoms,
with those related to the treatment of arthralgia as
the most frequent (64 %). We also found an unex-
pectedly high rate of ulcer and gastritis symptoms
(17 %), probably due to corticosteroids administered
during the active treatment phase. The high rate of
infection (about 40 %) occurred in the context of
moderate or mild hypogammaglobulinemia, suggesting
the presence of other mechanisms of immunosuppres-
sion, perhaps due to profound and durable B-cell de-
pletion induced by rituximab. Sexual dysfunction was
also frequent, as previously reported [38]. However,
Table 4 Bi-and multivariate analysis for the identification of groups at risk for developing at least one psychological disorder during
one year of follow-up (n = 104)
Crude OR 95 % CI p - Value Adjusted OR 95 % CI p - Value
Gender
Men 1.00 (Ref.) 1.00 (Ref.)
Women 2.90 (1.35; 6.23) 0.0064 7.14 (1.95; 26.16) 0.003
Age
≤ 60 1.00 (Ref.) 1.00 (Ref.)
> 60 0.32 (0.14; 0.71) 0.0051 0.79 (0.11; 5.58) 0.8155
Level of education
Lower educational status (≤high school degree) 1.00 (Ref.) 1.00 (Ref.)
Higher educational status (>high school degree) 1.85 (0.88; 3.92) 0.1066 1.66 (0.52; 5.32) 0.3929
Occupational status
In activity (employed) 1.00 (Ref.) 1.00 (Ref.)
Without activity (retired, unemployed) 0.59 (0.28; 1.24) 0.1627 2.49 (0.45; 13.98) 0.2987
Histology
Diffuse large B-cell lymphoma 1.00 (Ref.) 1.00 (Ref.)
Hodgkin lymphoma 7.7 (2.25; 26.36) 0.0011 25.46 (4.00; 162.13) 0.0006
Other non-Hodgkin lymphoma 1.83 (0.77; 4.36) 0.1698 3.73 (0.87; 16.05) 0.0709
Charlson Comorbidity Index
0 1.00 (Ref.) 1.00 (Ref.)
1 0.33 (0.06; 1.67) 0.1786 0.69 (0.08; 6.03) 0.7396
≥ 2 0.57 (0.20; 1.66) 0.306 0.63 (0.14; 2.91) 0.5536
First-line treatment
Intensified 1.00 (Ref.) 1.00 (Ref.)
Conventional 0.73 (0.293; 1.82) 0.5014 0.39 (0.07; 2.07) 0.2682
Health-related quality of life (SF-36) at M0
Physical component score 0.95 (0.93; 0.97) <.0001 0.98 (0.94; 1.02) 0.375
Mental component score 1.07 (1.04; 1.09.) <.0001 0.93 (0.89; 0.97) 0.0009
NOTE: Covariates were chosen with a cut-off value <0.20 in the bivariate analysis, except for the covariate first-line treatment
Abbreviations: OR Odds Ratio; CI Confidence Interval; SF-36 36-item short-form health survey
Model: adjusted for: gender, age, level of education, occupation, histology, Charlson comorbidity index, type of first-line treatment, health-related quality of life
(mental and physical component score)
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the most disabling complication was neuropathy
(24 %), as also previously reported [39, 40].
Newly-diagnosed comorbidities were unexpectedly
high, particularly cardiovascular diseases and second
cancers (almost 20 % of patients). This unprecedented
finding is intriguing since the majority of our patients
were relatively young, in good health, with a low CCI. It
is possible that comorbidities have been underestimated
in the early trajectory of lymphoma patients treated with
R-CHOP or R-CHOP-derived. The CT scan performed
at 6 months allowed the detection of pancreatic tumours
(n = 2), asymptomatic severe biliary disease (n = 1) and a
pulmonary embolism (n = 1). However, in terms of qual-
ity of lymphoma surveillance the CT scan was poor, in
agreement with other studies which do not support the
use of routine CT scan imaging for the follow-up of
DLBCL [15]. In the context of the frequent non-
haematological complications observed, AMA-AC was
found to be helpful in facilitating the coordination be-
tween the GP, the oncologist and the relevant specialist
in order to define priorities and new trajectories. How-
ever, it is interesting to note that, in most cases, even
when these complications were diagnosed by the GP, the
oncologist was requested before the patient was referred
to another specialist. The reason for this is that GPs
tend to relate symptoms to relapse before considering
the possibility of associated diseases, including the most
frequent (vascular complications and second cancers).
This experience places the AMA unit in a central pos-
ition for general medical management, this role being re-
inforced by the special links established with the patient
along their trajectory.
Furthermore, based on psychometric measurements it
seems that AMA-AC may also be an effective procedure
for detecting psychological disorders (e.g., anxiety, de-
pression and PTSD). These complications are thought to
be underestimated in cancer survivorship, mainly be-
cause hospital-based follow-up is poorly adapted. This is
due in part to heavy overbooking of the oncology unit
but is also related to the lack of education or even inter-
est of oncologists in onco-psychology. This latter state-
ment is reflected in the negative perception of patients
in terms of the role of the oncologist in managing such
complications [41–43], and suggests the need for the
development of new interventions such as AMA-AC to
address the psychosocial and physical concerns through-
out the course of the cancer trajectory [41]. Our study
found that 42 % of patients presented with at least one
psychological disorder during the first year of follow-up.
These results are in agreement with retrospective trans-
versal and longitudinal studies dealing with both HL and
NHL [2, 3, 44–46]. However, our prospective study
shows that the development of psychological disorders
in lymphoma survivorship changes over time and that
psychological support is essentially needed at the be-
ginning of the after-cancer trajectory as has been de-
scribed for other cancers including breast and ovarian
cancers [47].
AMA-AC also appears to be an effective method for
monitoring social changes including absenteeism and re-
turn to work. Among the patients in employment, 73 %
returned to work within 12 months. This percentage
was higher in HL compared to NHL, as previously
reported [48], and this rate is also in agreement with a
recent Danish registry study (1,741 patients) [4]. Due to
the relatively low number of patients monitored in our
study, it is not possible to draw any conclusions about
the possible role of AMA-AC in facilitating return to
work. However, we found AMA-AC to help facilitate
communication and coordination between oncologists,
NCs, GPs and occupational health professionals, which
is helpful for adapting the return to work to the patient’s
physical and mental capacities.
AMA-AC appears to be a simple procedure for moni-
toring HRQoL in routine practice. In lymphoma pa-
tients, HRQoL has been mainly investigated through
cross-sectional studies and less frequently in prospective
studies. From these previous studies, it appears that up
to one third of patients experience an alteration in their
HRQoL which is severe compared to other cancers,
some of which are more aggressive [49], and is often
enduring [1]. The present study shows that, although
HRQoL improved between M0 and M12, it remained
significantly affected one year after completion of treat-
ment in about 20 % of patients even when the PCS and
MCS scores were not adjusted for age.
Multivariate analysis allowed us to identify a number
of risk factors associated with the occurrence of psycho-
logical disorders. HL appears to be a significant param-
eter, as has previously been suggested [50]. Female
gender also appears to be an independent risk factor, as
suggested by a recent meta-analysis [51]. Lower MCS
after completion of chemotherapy is also highly predict-
ive of the occurrence of psychological disorders. These
results suggest that patients with a combination of risk
factors (female, advanced HL, with lower MCS after
therapy - in most cases associated with poor tolerability)
would benefit from adequate psychological support
during the early trajectory.
Our study suffers from several limits. First, our cohort
presented some degree of heterogeneity in terms of hist-
ology subtype, chemotherapy and risk of relapse, even
though all patients presented with advanced diseases
and were treated with prolonged anthracycline-based
chemotherapy. Moreover, several characteristics reflect a
patient selection bias such as age, education level and
fitness. These parameters, as well as the introduction of
AMA1 in our institution, may have affected the
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acceptance and adherence to the AMA-AC procedure.
The next step in determining the usability of AMA-AC
is to assess the medico-economics and to conduct a sat-
isfaction survey for patients and GPs. We are currently
performing several studies to investigate these important
aspects.
Conclusion
AMA-AC appears to be a promising alternative to the
standard follow-up for lymphoma survivorship surveil-
lance. It is a feasible and reproducible procedure, which
was found to be very effective in detecting physical
events (including new non-haematological diseases),
psychological disorders and social problems (including
return to work). AMA-AC represents a “shared care”
model which attributes the premium roles to the NC
and GPs. Further studies comparing AMA-AC with the
oncologist-based follow-up procedure are now needed to
establish AMA-AC as a standard surveillance method for
both non-haematological and haematological malignancies.
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